G. Barosi, G. Viarengo, and A. Pecci, Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia, Blood, vol.98, issue.12, pp.3249-3255, 2001.
DOI : 10.1182/blood.V98.12.3249

B. Andréasson, B. Swolin, and J. Kutti, Patients with idiopathic myelofibrosis show increased CD34+ cell concentrations in peripheral blood compared to patients with polycythaemia vera and essential thrombocythaemia, European Journal of Haematology, vol.36, issue.4, pp.189-193, 2002.
DOI : 10.1034/j.1600-0609.2001.066005324.x

F. Passamonti, L. Vanelli, and L. Malabarba, Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders, Haematologica, vol.88, pp.1123-1129, 2003.

B. Arora, S. Sirhan, J. Hoyer, R. Mesa, and A. Tefferi, Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients, British Journal of Haematology, vol.106, issue.1, pp.42-48, 2005.
DOI : 10.1111/j.1365-2141.2004.05280.x

D. Arber, A. Orazi, and R. Hasserjian, The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, vol.127, issue.20, pp.2391-2405, 2016.
DOI : 10.1182/blood-2016-03-643544

T. Klampfl, H. Gisslinger, and A. Harutyunyan, Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms, New England Journal of Medicine, vol.369, issue.25, pp.2379-2390, 2013.
DOI : 10.1056/NEJMoa1311347

A. Tefferi, J. Thiele, A. Vannucchi, and T. Barbui, An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms, Leukemia, vol.9, issue.7, pp.1407-1413, 2014.
DOI : 10.1038/leu.2014.35

I. Dobo, N. Boiret, and E. Lippert, A standardized endogenous megakaryocytic erythroid colony assay for the diagnosis of essential thrombocythemia, Haematologica, vol.89, pp.1207-1212, 2004.

E. Rumi, D. Pietra, and C. Pascutto, Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis, Blood, vol.124, issue.7, pp.1062-1069, 2014.
DOI : 10.1182/blood-2014-05-578435

A. Tefferi, P. Guglielmelli, and D. Larson, Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis, Blood, vol.124, issue.16, pp.2507-2513, 2014.
DOI : 10.1182/blood-2014-05-579136

M. Massa, V. Rosti, and I. Ramajoli, , and Vascular Endothelial Growth Factor Receptor 2???Positive Endothelial Progenitor Cells in Myelofibrosis With Myeloid Metaplasia, Journal of Clinical Oncology, vol.23, issue.24, pp.5688-5695, 2005.
DOI : 10.1200/JCO.2005.09.021

D. Pietra, E. Rumi, and V. Ferretti, Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms, Leukemia, vol.90, issue.2, pp.431-438, 2016.
DOI : 10.1038/leu.2014.270